Eli Lilly (LLY)
(Delayed Data from NYSE)
$806.06 USD
-0.08 (-0.01%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $806.00 -0.06 (-0.01%) 5:08 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$806.06 USD
-0.08 (-0.01%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $806.00 -0.06 (-0.01%) 5:08 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Eli Lilly (LLY) Tops Q4 Earnings & Sales, Keeps 2020 View
by Kinjel Shah
Eli Lilly's (LLY) Q4 earnings and sales beat estimates. Shares rise in pre-market trading.
5 Top Non-Tech Earnings Charts
by Tracey Ryniec
It's not all about technology or social media companies. These 5 companies are also in the earnings spotlight.
Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review
by Zacks Equity Research
The FDA accepts for review Alkermes' (ALKS) NDA for ALKS 3831 for the treatment of schizophrenia and bipolar I disorder and has set an action date of Nov 15, 2020.
Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More
by Zacks Equity Research
Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.
Merck's Dificid Gets FDA Approval in Pediatric Indication
by Indrajit Bandyopadhyay
The FDA grants approval to Merck's (MRK) two regulatory applications seeking expanded approval for its antibacterial medicine, Dificid.
AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study
by Zacks Equity Research
AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.
Lilly's Olumiant Meets Primary Goal in Dermatitis Study
by Zacks Equity Research
Eli Lilly (LLY) and partner Incyte's Olumiant meets primary endpoint in atopic dermatitis in a late-stage study.
Dr. Reddy's (RDY) Q3 Earnings and Revenues Increase Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings (excluding impairment charge) increase year over year in the third quarter of fiscal 2020.
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with older products lead to an earnings beat for the company.
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $139.07 in the latest trading session, marking a -1.52% move from the prior day.
J&J's Stelara Gets EU Nod for Plaque Psoriasis in Children
by Zacks Equity Research
Johnson & Johnson (JNJ) receives the European Commission's (EC) nod to the line extension of Stelara to treat six to 11-year-old pediatric patients with moderate-to-severe plaque psoriasis.
The Zacks Analyst Blog Highlights: Pfizer, Wells Fargo, SAP, salesforce.com and Eli Lilly
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Wells Fargo, SAP, salesforce.com and Eli Lilly
Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review
by Zacks Equity Research
Glaxo's (GSK) BLA for belantamab mafodotin gains the FDA priority review status to treat heavily pre-treated patients with relapsed or refractory multiple myeloma.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FTCS
Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Wells Fargo (WFC) and SAP SE (SAP).
Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates
by Kinjel Shah
Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.
Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction
by Zacks Equity Research
Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $141.43, moving +0.23% from the previous trading session.
J&J Seeks Label Expansion for Spravato Nasal Spray in EU
by Zacks Equity Research
J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.
Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA
by Zacks Equity Research
The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.
Nektar's Pain Drug Gets Adverse Advisory Committee Decision
by Zacks Equity Research
Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.
Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins
by Zacks Equity Research
Eli Lilly (LLY) announced plans to launch cheaper version of its Humalog insulins, Mix75/25 KwikPen and Junior KwikPen.
Glaxo Files Marketing Application for Fostemsavir in Europe
by Zacks Equity Research
Glaxo (GSK) submits an MAA in Europe for its investigational candidate fostemsavir, which is being developed for treating HIV-1 infection in heavily pre-treated adult HIV patients.
Company News for Jan 13, 2020
by Zacks Equity Research
Companies In The News Are: SNX, KBH, WDFC, LLY.